Catalyst Pharmaceuticals, Inc.
CPRX
Rank in Stocks
#4169
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Share Price
$31.49
Last synced: 2026-07-21
Market Cap
$3.85B
Change (1 day)
0.00%
Change (1 year)
49.88%
Country
US
Trade Catalyst Pharmaceuticals, Inc. (CPRX)
Category
Healthcare
Number of shares outstanding for Catalyst Pharmaceuticals, Inc. (CPRX)
Number of shares outstanding as of March 2026: 122.25M
According to Catalyst Pharmaceuticals, Inc. latest financial reports and stock price the company's current number of shares outstanding is 122.25M. At the end of December 2023 the company had 106.28M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Catalyst Pharmaceuticals, Inc. (CPRX) from 2002 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 122.25M | 3.20% |
| 2024 | 118.46M | 11.46% |
| 2023 | 106.28M | 2.81% |
| 2022 | 103.37M | 0.00% |
| 2021 | 103.38M | -0.13% |
| 2020 | 103.51M | 0.55% |
| 2019 | 102.94M | 0.30% |
| 2018 | 102.63M | 19.62% |
| 2017 | 85.80M | 3.53% |
| 2016 | 82.88M | 2.49% |
| 2015 | 80.86M | 26.06% |
| 2014 | 64.14M | 41.12% |
| 2013 | 45.45M | 51.34% |
| 2012 | 30.03M | 38.22% |
| 2011 | 21.73M | 16.94% |
| 2010 | 18.58M | 23.32% |
| 2009 | 15.07M | 15.78% |
| 2008 | 13.01M | 3.89% |
| 2007 | 12.53M | 62.93% |
| 2006 | 7.69M | 23.90% |
| 2005 | 6.20M | 112.61% |
| 2004 | 2.92M | 0.00% |
| 2003 | 2.92M | 23.73% |
| 2002 | 2.36M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 107.68% |
US
|
|
| 396.00M | 223.92% |
US
|
|
| 478.91M | 291.73% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -49.13% |
NL
|
